Skip to content
Sign in
European CDMOs compared · 2026 census

CDMOs in Finland: 5 compared (2026)

5 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in Finland. None has revenue over €1bn. 2 sit between €250m and €1bn and 3 are smaller or niche.

By ownership: 1 family-owned, 1 private equity, 1 listed and 2 part of a pharma or industrial group. The most common capabilities are small-molecule API (3), biologics and biosimilars (2), oral solid dose (1), viral vector and vaccine (1) and cell and gene therapy (1). 3 of the 5 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.

Open these 5 in the interactive mapAll 255 European CDMOs

5 companies

CDMOs in Finland

CompanyHQOwnershipSizeRevenue (as reported)ModalitiesData
FermionOrion's dedicated CDMO arm; small-molecule API CDMO (Phase I→commercial) incl. HPAPI/cytotoxic. Two FDA/EMA-approved API sites.EspooPart of a pharma or industrial groupOrion CorporationTier 2not disclosedSmall-molecule API, Oral solid dosehigh
FinVectorcGMP viral-vector (adenoviral) gene-therapy manufacturer, FDA-approved. Now Ferring-owned and its new plant is dedicated to parent's own product — reads more captive than open CDMO.KuopioPart of a pharma or industrial groupFerringTier 2not disclosedViral vector and vaccine, Cell and gene therapylow
NanoformNanoparticle drug-particle-engineering CDMO (CESS nanoforming for small molecules + a biologics platform); formulation, analytical + GMP API. Nasdaq First North.HelsinkiListedTier 3not disclosedSmall-molecule API, Biologics and biosimilarshigh
Paras BiopharmaceuticalsFounder-led microbial-biologics CDMO: recombinant biologics/biosimilars in microbial systems, plus peptides and proteins. Scales 10L→750L+.OuluFamily-ownedTier 3not disclosedBiologics and biosimilars, Microbial and protein, Peptidemedium
PharmatoryFinnish CDMO: small-molecule synthesis, process R&D, cGMP API contract manufacturing and analytics for human and veterinary pharma.OuluPrivate equityMB FundsTier 3not disclosedSmall-molecule APIhigh

Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).

Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.

Browse the census

Other European CDMO lists